{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:14:36Z","timestamp":1790255676282,"version":"4.1.0"},"reference-count":42,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Use &amp;amp; Addiction Journal"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The United States is grappling with an unprecedented overdose crisis, exacerbated by the proliferation of potent synthetic opioids like illicitly manufactured fentanyl. Despite the efficacy of methadone treatment in managing opioid use disorder, regulatory barriers hinder its widespread utilization. This article examines the complex landscape of methadone regulation across federal, state, and local levels, highlighting disparities and opportunities for reform.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Issue:<\/jats:title>\n                    <jats:p>The COVID-19 public health emergency prompted temporary flexibility in methadone regulations, including expanded take-home doses and telehealth counseling, leading to improved treatment experiences and retention. Permanent revisions to federal guidelines have since been introduced by the Substance Abuse and Mental Health Services Administration, reflecting a progressive shift toward patient-centered care and streamlined access. State regulations, managed by Single State Agencies and State Opioid Treatment Authorities, vary widely, often imposing additional restrictions that impede access to methadone treatment. Local OTP clinics further exacerbate barriers through stringent policies, despite federal and state guidelines advocating for flexibility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recommendations:<\/jats:title>\n                    <jats:p>Coordinated efforts among policymakers, healthcare providers, and communities are needed to promote the development of accountability measures, incentives, and community involvement to ensure equitable access and quality of care. To truly meet the demand needed to end the existing overdose crisis and enhance accessibility and comprehensive healthcare services, methadone treatment expansion beyond traditional OTP settings into primary care offices and community pharmacies should take place.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/29767342241255480","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T07:58:05Z","timestamp":1716883085000},"page":"337-345","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Methadone\u2019s Resurgence in Bridging the Treatment Gap in the Overdose Crisis: Position Statement of AMERSA, Inc (Association for Multidisciplinary Education, Research, Substance Use, and Addiction)"],"prefix":"10.1177","volume":"45","author":[{"given":"Leslie W.","family":"Suen","sequence":"first","affiliation":[{"name":"University of California San Francisco Division of General Internal Medicine at San Francisco General Hospital, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1468-930X","authenticated-orcid":false,"given":"Michael","family":"Incze","sequence":"additional","affiliation":[{"name":"University of Utah Division of General Internal Medicine, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5677-297X","authenticated-orcid":false,"given":"Caty","family":"Simon","sequence":"additional","affiliation":[{"name":"National Survivors Union, Greensboro, NC, USA"},{"name":"Whose Corner Is It Anyway, Holyoke, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honora","family":"Englander","sequence":"additional","affiliation":[{"name":"Department of Medicine, Oregon Health & Science University, Portland, OR, USA"},{"name":"Service Universitaire d\u2019Addictologie de Lyon (SUAL), Hospices Civils de Lyon, CH Le Vinatier, Universit\u00e9 Claude-Bernard Lyon 1, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2240-5768","authenticated-orcid":false,"given":"Jeffrey","family":"Bratberg","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Clinical Research, University of Rhode Island College of Pharmacy, Kingston, RI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Groves Scott","sequence":"additional","affiliation":[{"name":"St. Joseph\u2019s University, Philadelphia, PA, USA"},{"name":"Health Policy Network, LLC, Lancaster, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Winograd","sequence":"additional","affiliation":[{"name":"Department of Psychological Sciences, University of Missouri, St. Louis, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,5,28]]},"reference":[{"key":"bibr1-29767342241255480","unstructured":"Ahmad FB, Cisewski JA, Rossen LM, Sutton. Provisional Drug Overdose Death Counts. National Center for Health Statistics; 2023. Accessed September 18, 2023. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm"},{"key":"bibr2-29767342241255480","unstructured":"Mann B. Drug overdose deaths surge among black Americans during pandemic. NPR.org. 2021. Accessed March 11, 2021. https:\/\/www.npr.org\/2021\/03\/03\/970964576\/drug-overdose-deaths-surge-among-black-americans-during-pandemic"},{"key":"bibr3-29767342241255480","doi-asserted-by":"publisher","DOI":"10.17226\/25310"},{"key":"bibr4-29767342241255480","unstructured":"Institute of Medicine, (US) Committee on Federal Regulation of Methadone Treatment. Federal Regulation of Methadone Treatment. National Academies Press; 1995. Accessed May 29, 2021. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK232108\/"},{"key":"bibr5-29767342241255480","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2021.306665"},{"key":"bibr6-29767342241255480","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-021-00535-y"},{"key":"bibr7-29767342241255480","doi-asserted-by":"publisher","DOI":"10.1101\/2022.12.15.22283533"},{"key":"bibr8-29767342241255480","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2022.2060438"},{"key":"bibr9-29767342241255480","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-021-00281-3"},{"key":"bibr10-29767342241255480","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108288"},{"key":"bibr11-29767342241255480","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108801"},{"key":"bibr12-29767342241255480","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-022-07939-x"},{"key":"bibr13-29767342241255480","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.12562"},{"key":"bibr14-29767342241255480","unstructured":"Substance Abuse and Mental Health Services Administration. Opioid treatment program (OTP) guidance. 2020. Accessed January 5, 2021. https:\/\/www.samhsa.gov\/sites\/default\/files\/otp-guidance-20200316.pdf"},{"key":"bibr15-29767342241255480","unstructured":"Substance Abuse and Mental Health Services Administration. Methadone take-home flexibilities extension guidance. 2021. Accessed January 4, 2024. https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/statutes-regulations-guidelines\/methadone-guidance"},{"key":"bibr16-29767342241255480","unstructured":"Baaklini V, Doyle S, McGaffey F. Most States Eased Access to Opioid Use Disorder Treatment During the Pandemic. Pew Charitable Trusts Substance Use Prevention and Treatment Initiative; 2022. Accessed January 4, 2024. https:\/\/pew.org\/3ayPrSD"},{"key":"bibr17-29767342241255480","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0274094"},{"key":"bibr18-29767342241255480","unstructured":"Joseph A. Under new rules, methadone clinics can offer more take-home doses. Will they? STAT. 2022. Accessed January 4, 2024. https:\/\/www.statnews.com\/2022\/12\/22\/new-rules-methadone-clinics-take-home-doses\/"},{"key":"bibr19-29767342241255480","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2022.1776"},{"key":"bibr20-29767342241255480","unstructured":"Substance Abuse and Mental Health Services Administration. 42 CFR part 8 final rule. 2024. Accessed March 2, 2024. https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/statutes-regulations-guidelines\/42-cfr-part-8"},{"key":"bibr21-29767342241255480","unstructured":"McCarty D. The Single State Authority: Origins and Responsibilities. Addiction Technology Transfer Center Network; 2019. Accessed January 4, 2024. https:\/\/attcnetwork.org\/centers\/attc-network-coordinating-office\/single-state-authority-origins-and-responsibilites"},{"key":"bibr22-29767342241255480","unstructured":"Substance Abuse and Mental Health Services Administration. State opioid treatment authorities. 2020. Accessed January 22, 2024. https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/sota"},{"key":"bibr23-29767342241255480","first-page":"240","volume":"12","author":"Lewis JS.","year":"1988","journal-title":"Alcohol Health Res World"},{"key":"bibr24-29767342241255480","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104141"},{"key":"bibr25-29767342241255480","unstructured":"Pew Research Center. Overview of Opioid Treatment Program Regulations by State. Pew Charitable Trusts; 2022. Accessed October 6, 2022. https:\/\/pew.org\/3Qw8g8c"},{"key":"bibr26-29767342241255480","doi-asserted-by":"publisher","DOI":"10.1017\/jme.2023.73"},{"key":"bibr27-29767342241255480","unstructured":"Duff JH, Carter JA. Location of Medication-Assisted Treatment for Opioid Addiction: In Brief. Congressional Research Service; 2019. Accessed January 4, 2024. https:\/\/sgp.fas.org\/crs\/misc\/R45782.pdf"},{"key":"bibr28-29767342241255480","doi-asserted-by":"publisher","DOI":"10.1093\/haschl\/qxad018"},{"key":"bibr29-29767342241255480","unstructured":"Substance Abuse and Mental Health Services Administration. Statutes, regulations, and guidelines. 2015. Accessed January 4, 2024. https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/statutes-regulations-guidelines"},{"key":"bibr30-29767342241255480","unstructured":"Substance Abuse and Mental Health Services Administration. Federal Guidelines for Opioid Treatment Programs. Substance Abuse and Mental Health Services Administration; 2015:82."},{"key":"bibr31-29767342241255480","doi-asserted-by":"publisher","DOI":"10.1377\/forefront.20230531.974690"},{"key":"bibr32-29767342241255480","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2021.306654"},{"key":"bibr33-29767342241255480","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2022.306806"},{"key":"bibr34-29767342241255480","unstructured":"New York State Office of Addiction Services and Supports. OASAS OTP Bundle Billing Guidance. 2024. Accessed May 19, 2024. https:\/\/oasas.ny.gov\/system\/files\/documents\/2024\/04\/nys-medicaid-otp-bundled-fees-guidance-march-2024-final.pdf"},{"key":"bibr35-29767342241255480","doi-asserted-by":"publisher","DOI":"10.1377\/forefront.20220524.911965"},{"key":"bibr36-29767342241255480","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2021.1975344"},{"key":"bibr37-29767342241255480","unstructured":"Pew Research Center. How can patients access methadone in other countries? 2023. Accessed January 4, 2024. https:\/\/pew.org\/3M8T297"},{"key":"bibr38-29767342241255480","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.10.1343"},{"key":"bibr39-29767342241255480","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S61014"},{"key":"bibr40-29767342241255480","doi-asserted-by":"publisher","DOI":"10.1093\/haschl\/qxad061"},{"key":"bibr41-29767342241255480","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108766"},{"key":"bibr42-29767342241255480","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.9.817"}],"container-title":["Substance Use &amp;amp; Addiction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342241255480","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/29767342241255480","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342241255480","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:49:53Z","timestamp":1777600193000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/29767342241255480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1177\/29767342241255480"],"URL":"https:\/\/doi.org\/10.1177\/29767342241255480","relation":{},"ISSN":["2976-7342","2976-7350"],"issn-type":[{"value":"2976-7342","type":"print"},{"value":"2976-7350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,28]]}}}